Related Experiment Video
Updated: Apr 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
The role of heart failure pharmacotherapy after left ventricular assist device support
John J Rommel1, Thomas J O'Neill1, Anton Lishmanov1
1Division of Cardiology, Department of Medicine, The University of North Carolina at Chapel Hill, 160 Dental Circle, 6th Floor Burnett-Womack Building, Chapel Hill, NC 27599-7075, USA.
Abstract:
Left ventricular assist devices (LVADs) are an increasingly common treatment for end-stage systolic heart failure. However, there are limited data on how to best treat patients pharmacologically after LVAD implantation, resulting in uncertainty about which heart failure medications provide the most benefit. Still, some evidence exists that certain medical therapies can prevent remodeling and improve right ventricular and, possibly, left ventricular function. This article reviews the current literature for medical heart failure therapy in LVAD patients, and possible future treatment strategies.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VII: Nursing Interventions

